Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04826341
Title	A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	lung small cell carcinoma Advanced Solid Tumor neuroendocrine carcinoma
Therapies	Berzosertib + Sacituzumab govitecan-hziy
Age Groups:	adult \| senior
Covered Countries	USA